TabMenu

Poverty and InequalitySexual and Reproductive HealthFamily, Maternal & Child HealthMethodology

Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study

TitleContinuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study
Publication TypeJournal Article
Year of Publication2018
AuthorsJensen, JT, Edelman, AB, Chen, BA, Archer, DF, Barnhart, KT, Thomas, MA, Burke, AE, Westhoff, CL, Wan, LS, Sitruk-Ware, R, Kumar, N, Variano, B, Blithe, DL
JournalContraception
Volume97
Pagination422-427
Type of ArticleArticle
ISBN Number00107824 (ISSN)
KeywordsAdult, Area under the curve, article, concentration at steady-state, Continuous cycling, contraception, Contraceptive vaginal ring, controlled study, double blind procedure, drug blood level, elcometrine, Estradiol, Female, human, human experiment, maximum plasma concentration, multicenter study, Nestorone, normal human, pharmacokinetics, phase 2 clinical trial, Prospective study, randomized controlled trial, time to maximum plasma concentration
Abstract

Background: As part of a program to develop a novel estradiol-releasing contraceptive vaginal ring (CVR), we evaluated the pharmacokinetic (PK) profile of CVRs releasing segesterone acetate (Nestorone® (NES)) combined with one of three different estradiol (E2) doses. Study design: A prospective, double-blind, randomized, multi-centered study to evaluate a 90-day CVR releasing NES [200 mcg/day] plus E2, either 10 mcg/day, 20 mcg/day, or 40 mcg/day in healthy reproductive-age women with regular cycles. Participants provided blood samples twice weekly for NES and E2 levels during the first 60 days (ring 1) and the last 30 days (ring 2) of use. A subset underwent formal PK assessments at ring initiation, ring exchange (limited PK), and study completion. Results: The main study enrolled 197 women; 22 participated in the PK substudy. Baseline characteristics between the main and PK participants were comparable, with an average BMI of 25.8 kg/m2 (SD 4.3). In the PK substudy, all three rings showed similar NES PK: mean area under the curve (AUC(0–72)) 34,181 pg*day/mL; concentration maximum (Cmax) 918 pg/mL; time to maximum concentration (Tmax) 3.5 h. For E2, the Cmax occurred at 2 h, and was significantly higher with the 20 mcg/day ring (mean 390 pg/mL); 10 mcg/day, 189 pg/mL, p=.003; 40 mcg/day, 189 pg/mL, p<.001), and declined rapidly to≤50 pg/mL for all doses by 24 h. For all subjects, the median E2 levels remained under 35 pg/mL during treatment. Conclusion: PK parameters of NES were not affected when paired with different doses of E2, but E2 levels from all three doses were lower than anticipated and no dose response was observed. Implications: While these novel estradiol-releasing combination contraceptive vaginal rings provided sustained release of contraceptive levels of Nestorone over 90 days, the E2 levels achieved were not consistent with bone protection, and a dose–response was not observed. © 2018 Elsevier Inc.